AN2 Therapeutics, Inc. Payments of Stock Issuance Costs
AN2 Therapeutics, Inc. (ANTX) reported Payments of Stock Issuance Costs of $1.21 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-03-29
- AN2 Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2021-12-31 was $970.00K.
- AN2 Therapeutics, Inc. payments of stock issuance costs for fiscal 2021 was $1.21M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|
| 2021-12-31 | $970.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $1.21M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $240.00K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |